Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

Saved in:

Bibliographic Details
Main Authors:	Goldschmidt, Hartmut (Author) , Mai, Elias K. (Author) , Hose, Dirk (Author) , Jauch, Anna (Author) , Hillengaß, Jens (Author) , Raab, Marc-Steffen (Author) , Bertsch, Uta (Author) , Hielscher, Thomas (Author)
Format:	Article (Journal)
Language:	English
Published:	2018
In:	Leukemia Year: 2018, Volume: 32, Pages: 383-390
ISSN:	1476-5551
DOI:	10.1038/leu.2017.211
Online Access:	Verlag, Volltext: http://dx.doi.org/10.1038/leu.2017.211 Verlag, Volltext: https://www.nature.com/articles/leu2017211
Author Notes:	H. Goldschmidt, H.M Lokhorst, E.K. Mai, B. van der Holt, I.W. Blau, S. Zweegman, K.C. Weisel, E. Vellenga, M. Pfreundschuh, M.J. Kersten, C. Scheid, S. Croockewit, R. Raymakers, D. Hose, A. Potamianou, A. Jauch, J. Hillengass, M. Stevens-Kroef, M.S. Raab, A. Broijl, H.W. Lindemann, G.M.J. Bos, P. Brossart, M. van Marwijk Kooy, P. Ypma, U. Duehrsen, R.M. Schaafsma, U. Bertsch, T. Hielscher, Le Jarari, H.J. Salwender and P. Sonneveld

Similar Items